February 23, 2016: Here are four stocks trading with heavy volume among 46 equities making new 52-week lows today. PTC Therapeutics Inc. (NASDAQ: PTCT) dropped about 59% on Tuesday to post a new...
Chimerix had a bad start to the week as it tumbled in early trading on Monday, following some late stage clinical trial results.
December 28, 2015: Here are four stocks trading with heavy volume among 34 equities making new 52-week lows today. Chimerix Inc. (NASDAQ: CMRX) dropped about 81% on Monday to post a new 52-week low...
Chimerix reported mixed fourth-quarter financial results before the markets opened on Monday.
The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola drugs might not be a cure-all for patients.
Tuesday's top analyst calls were in shares of Albermarle, Atara Biotherapeutics, Chimerix, IHS, NetApp, Pure Storage and more.
Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.
Chimerix absolutely led the bears in Monday’s trading session on less-than-favorable results from a late-stage trial.
Investors and traders alike always seem to be on the lookout for new speculative investment ideas that can generate massive long-term or short-term gains. While investors get to see many Buy ratings...
Chimerix has announced that its lead drug candidate has been provided for potential use in patients with Ebola virus disease.
Tuesday's top analyst upgrades, downgrades and initiations include Barclays, Caterpillar, EMC, JD.com, LinkedIn and Stratasys.
Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brought a mixed view for this group.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, February 13, 2014. They include Angie's List, Itron, NVIDIA, Regeneron and Sempra...
With the summer doldrums over, the stock market is starting to return to normal. We also saw some very large insider selling in a top European pharmaceutical stock.
Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears.